Covered recipient · General Payments record
RICHA GUPTA JAIN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2024
$1,383.33
- Reported across 69 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $489.33 | 33 |
| Education | $8.90 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $152.92 | 9 |
| ABBVIE INC. | $132.84 | 13 |
| Lilly USA, LLC | $49.26 | 3 |
| Astellas Pharma US Inc | $36.96 | 2 |
| Amgen Inc. | $28.06 | 2 |
| Axsome Therapeutics, Inc. | $25.75 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.81 | 1 |
| Abbott Laboratories | $18.05 | 1 |
| Acerta Pharma LLC | $17.36 | 1 |
| GlaxoSmithKline, LLC. | $15.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202020222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.05 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125320743 | CMS |
| ABBVIE INC. | $14.13 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853273 | CMS |
| ABBVIE INC. | $11.70 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853275 | CMS |
| ABBVIE INC. | $8.08 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853277 | CMS |
| ABBVIE INC. | $1.98 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853279 | CMS |
| ABBVIE INC. | $21.37 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853281 | CMS |
| ABBVIE INC. | $24.85 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853283 | CMS |
| ABBVIE INC. | $1.51 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853285 | CMS |
| ABBVIE INC. | $8.08 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853287 | CMS |
| ABBVIE INC. | $6.98 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853289 | CMS |
| ABBVIE INC. | $8.77 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853291 | CMS |
| ABBVIE INC. | $7.22 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853293 | CMS |
| ABBVIE INC. | $11.19 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853295 | CMS |
| ABBVIE INC. | $6.98 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853297 | CMS |
| Amgen Inc. | $14.44 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117587447 | CMS |
| Amgen Inc. | $13.62 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117587449 | CMS |
| Astellas Pharma US Inc | $22.31 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139297898 | CMS |
| Astellas Pharma US Inc | $14.65 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139346932 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.36 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105317120 | CMS |
| Axsome Therapeutics, Inc. | $25.75 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148314342 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.81 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118213449 | CMS |
| GlaxoSmithKline, LLC. | $15.22 | 02/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116558189 | CMS |
| Lilly USA, LLC | $15.60 | 03/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135386207 | CMS |
| Lilly USA, LLC | $17.39 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135365220 | CMS |
| Lilly USA, LLC | $16.27 | 05/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135374720 | CMS |
| Novo Nordisk Inc | $16.27 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097403033 | CMS |
| Novo Nordisk Inc | $17.11 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097431311 | CMS |
| Novo Nordisk Inc | $16.68 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097202366 | CMS |
| Novo Nordisk Inc | $19.28 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097757302 | CMS |
| Novo Nordisk Inc | $8.90 | 07/25/2024 | Education | Undisputed | 01/23/2026 | 1096798880 | CMS |
| Novo Nordisk Inc | $19.67 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097040907 | CMS |
| Novo Nordisk Inc | $17.59 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097479670 | CMS |
| Novo Nordisk Inc | $17.24 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096616414 | CMS |
| Novo Nordisk Inc | $20.18 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097316218 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.